Avtor/Urednik		Južnič-Šetina, Tanja
Naslov		Karcinom dojke pri moškem
Tip		monografija
Kraj izdaje		Ljubljana
Založnik		Univerza v Ljubljani, Medicinska fakulteta
Leto izdaje		2006
Obseg		str. 55
Jezik		slo
Abstrakt		Male breast cancer is a rare disease. There are about 10 new cases diagnosed in Slovenia each year. It accounts for about 0.2% of all malignancies in men. Because of the rarity of the disease there are still a lot of questions concerning optimal management, prognostic variables and outcome. The aim of our retrospective study in which 85 male breast cancer patients treated at the Institute of Oncology befinreen 1968 and 2000 were included, was to find out patient and tumour characteristics of male breast cancer in Slovenia, factors that influence prognosis and survival in our patients. The median age of our patients was 61.5 years (range 20-83 yrs). Stage at presentation was known in 82 of 85 patients: UICC stage I-II 41 (50%) patients, stage III 28 (34%) patients, and stage IV 13 (16%) patients. All patients with stage I-II underwent radical surgery, 23 of them received adjuvant chemotherapy or hormonal therapy and 12 were locoregionally irradiated. Radical surgery was performed in 19/28 patients stage III disease, 16 of them received adjuvant therapy and 16 locoregional irradiation. Pathology data: 53 (73%) invasive ductal, 2 (3%) ductal carcinoma in situ, 2 (3%) invasive lobular and 15 (21%) other invasive carcinomas. Among the 63 patients with histologically known axillary lymph node status, 62% were axillary lymph node positive and 38% node negative. Hormonal receptors were positive in 86% of patiens with known hormonal receptor status. With a median follow up of 9 years, 5- and 10- year disease specific survival (DSS) of all our patients was 66% and 42% respectively. The 5- and 10-year disease free survival (DFS) of 70 patients with invasive cancer stage I-III was 63% and 43% and DSS 76.7°/o and 48.6% respectively. DFS and DSS were significantly affected by UICC stage, nodal status and tumor size. The 5-year DFS for stage I disease was 87.5%, stage II 80.7% and stage III 34.4%. DFS at 5 year was 87. (Abstract truncated at 2000 characters)
Deskriptorji		BREAST NEOPLASMS PROGNOSIS SURVIVAL ANALYSIS NEOPLASM STAGING LYMPHATIC METASTASIS RETROSPECTIVE STUDIES